Brainstorm Cell Therapeutics (BCLI)
(Delayed Data from NSDQ)
$0.28 USD
+0.01 (4.37%)
Updated Sep 13, 2024 03:59 PM ET
After-Market: $0.28 0.00 (-0.71%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrainstorm Cell Therapeutics Inc. (BCLI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$2.20 | $2.40 | $2.00 | 714.81% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Brainstorm Cell Therapeutics Inc. comes to $2.20. The forecasts range from a low of $2.00 to a high of $2.40. The average price target represents an increase of 714.81% from the last closing price of $0.27.
Analyst Price Targets (2 )
Broker Rating
Only one brokerage firm provided a Strong Buy-equivalent recommendation for Brainstorm Cell Therapeutics Inc. This translates to an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell). ABR is the calculated average of actual recommendations (Buy, Hold, Sell etc.) made by brokerage firms.
The current ABR compares to an ABR of 1.00 a month ago based on just one Strong Buy recommendation.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/11/2024 | Maxim Group | Jason Mccarthy | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 1 |
Average Target Price | $2.20 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | -0.03 |
BCLI FAQs
Brainstorm Cell Therapeutics Inc. (BCLI) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 1 brokerage firms.
The average price target for Brainstorm Cell Therapeutics Inc. (BCLI) is $2.20. The current on short-term price targets is based on 1 reports.
The forecasts for Brainstorm Cell Therapeutics Inc. (BCLI) range from a low of $2 to a high of $2.4. The average price target represents a increase of $685.71 from the last closing price of $.28.
The current UPSIDE for Brainstorm Cell Therapeutics Inc. (BCLI) is 685.71%
Based on short-term price targets offered by two analysts, the average price target for Brainstorm Cell Therapeutics Inc. comes to $2.20. The forecasts range from a low of $2.00 to a high of $2.40. The average price target represents an increase of 714.81% from the last closing price of $0.27.